CNBC Cures: Understanding rare disease

Summary

Becky Quick shares her family's experience after her daughter Kaylee was diagnosed with the rare neurodevelopmental condition SYNGAP1. She explains the science of SYNGAP1, the challenges rare-disease families face, and the launch of CNBC Cures, including a podcast, newsletter, and March 3 conference. The segment also highlights advances in AI, CRISPR, and ASO therapies and notes the difficulty of turning small-population research into treatments. No specific investment recommendations or named public securities are provided.

• Becky Quick discloses daughter Kaylee's SYNGAP1 diagnosis and family impact.
• SYNGAP1 is described as a brain protein deficiency causing seizures, autism, and developmental delays.
• Becky says rare diseases affect 1 in 10 Americans, 30 million in the U.S., and 400 million globally.
• CNBC Cures launches with a podcast, weekly newsletter, and March 3 New York conference.
• Research advances in AI, CRISPR, and ASO therapies may speed rare-disease treatment development.
• Small patient populations and diagnosis challenges complicate drug development and commercialization.
• John Crowley is cited as an example of rare-disease drug development and a large company exit.
• No specific investment recommendations or named public securities are provided.